CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $25.8M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 5.24: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.93BCNY287.60M · vs all stocks (USD)
Revenue (TTM)
173.47MCNY25.80M · vs all stocks (USD)
Profit Margin
-182.17%vs Biotechnology peers
Beta
0.1970xvs all stocks
52-Week Change
-59.84%vs all stocks
Market Capitalization
1.93BCNY287.60M · vs all stocks (USD)
Enterprise Value
1.61BCNY239.55M · vs all stocks (USD)
Forward P/E
11.40xvs Biotechnology peers
Price to Sales (TTM)
10.66xvs Biotechnology peers
Price to Book (MRQ)
2.10xvs Biotechnology peers
Enterprise to Revenue
9.29xvs Biotechnology peers
Enterprise to EBITDA
36.61xvs Biotechnology peers
Gross Margin
64.68%vs Biotechnology peers
Profit Margin
-182.17%vs Biotechnology peers
Operating Margin
20.64%vs Biotechnology peers
Return on Assets (TTM)
1.47%vs Biotechnology peers
Return on Equity (TTM)
-22.69%vs Biotechnology peers
Revenue (TTM)
173.47MCNY25.80M · vs all stocks (USD)
Revenue per Share (TTM)
0.2590CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-23.30%vs Biotechnology peers
Gross Profit (TTM)
119.61MCNY17.79M · vs all stocks (USD)
EBITDA (TTM)
454.12MCNY67.53M · vs all stocks (USD)
Net Income (TTM)
-316.00MCNY-46.99M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-41.90%vs Biotechnology peers
Operating Cash Flow (TTM)
68.11MCNY10.13M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
67.31MCNY10.01M · vs all stocks (USD)
Minority Interest (Equity)
13.93MCNYFY2025 · Dec 31, 2025Revenue
187.87MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
52.28MCNYFY2025 · Dec 31, 2025Gross Profit
135.59MCNYFY2025 · Dec 31, 2025Operating Income
47.07MCNY7.00M · vs all stocks (USD)
Pre-tax Income
-184.82MCNYFY2025 · Dec 31, 2025Income Tax Expense
107.34MCNYFY2025 · Dec 31, 2025Net Income
-292.16MCNYFY2025 · Dec 31, 2025EBIT
-183.55MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
468.08MCNYFY2025 · Dec 31, 2025Research & Development
22.67MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
16.78MCNYFY2025 · Dec 31, 2025Other Operating Expenses
2.48MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
6.88MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
1.26MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.4800CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.4800CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
648.83MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
648.83MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-292.16MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-19.28MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-176.50MCNYFY2025 · Dec 31, 2025Free Cash Flow
-188.08MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
211.66MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-292.16MCNYFY2025 · Dec 31, 2025Other Non-cash Items
5.73MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
16.27MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
93.67MCNYFY2025 · Dec 31, 2025Capital Expenditures
-11.59MCNYFY2025 · Dec 31, 2025Net Acquisitions
-21.51MCNYFY2025 · Dec 31, 2025Purchase of Investments
-371.62MCNYFY2025 · Dec 31, 2025Sale of Investments
303.45MCNYFY2025 · Dec 31, 2025Other Investing Activity
50.00MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-51.26MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
3.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-122.26MCNYFY2025 · Dec 31, 2025Other Financing Charges
-32.73MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-151.99MCNYFY2025 · Dec 31, 2025Shares Outstanding
651.90MSharesUpdated Aug 21, 2026Float Shares
350.87MSharesUpdated Aug 21, 2026% Held by Insiders
42.83%vs all stocks
% Held by Institutions
0.10%vs all stocks
Total Cash (MRQ)
387.72MCNY57.66M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.5950CNYUpdated Aug 21, 2026Total Debt (MRQ)
90.95MCNY13.52M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0972xvs Biotechnology peers
Current Ratio (MRQ)
4.27xvs Biotechnology peers
Book Value per Share (MRQ)
1.36CNYUpdated Aug 21, 2026Total Assets
1.13BCNY167.32M · vs all stocks (USD)
Total Current Assets
595.84MCNYFY2025 · Dec 31, 2025Total Liabilities
229.14MCNYFY2025 · Dec 31, 2025Total Non-current Assets
529.27MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
117.60MCNYFY2025 · Dec 31, 2025Total Current Liabilities
111.54MCNYFY2025 · Dec 31, 2025Cash
211.65MCNYFY2025 · Dec 31, 2025Cash Equivalents
2.66MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
214.31MCNYFY2025 · Dec 31, 2025Other Short-term Investments
210.84MCNYFY2025 · Dec 31, 2025Accounts Receivable
100.85MCNYFY2025 · Dec 31, 2025Inventory
59.46MCNYFY2025 · Dec 31, 2025Accounts Payable
8.33MCNYFY2025 · Dec 31, 2025Short-term Debt
6.19MCNYFY2025 · Dec 31, 2025Other Current Liabilities
2.01MCNYFY2025 · Dec 31, 2025Long-term Debt
10.40MCNYFY2025 · Dec 31, 2025Common Stock (Book)
655.66MCNYFY2025 · Dec 31, 2025Retained Earnings
28.29MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
895.97MCNY133.24M · vs all stocks (USD)
Treasury Stock
31.23MCNYFY2025 · Dec 31, 202552-Week Low
2.57CNYUpdated Aug 21, 202652-Week High
7.44CNYUpdated Aug 21, 202652-Week Change
-59.84%vs all stocks
Beta
0.1970xvs all stocks
50-Day MA
2.89CNYUpdated Aug 21, 2026200-Day MA
4.66CNYUpdated Aug 21, 2026Avg 10-Day Volume
7.35MSharesUpdated Aug 21, 2026Avg 30-Day Volume
6.48MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-0.4900CNYUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.65Profit Margin: -1.82
Financial Health
Altman Z-Score 5.24: safe zoneNotable
Altman Z-Score: 5.24
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $25.8M, lower than 95% of all stocks globallySignificant
Revenue (USD): 25,796,140.757Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Lineage Cell Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Inventage Lab Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sichuan Gangtong Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
CytoDyn Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cutia Therapeutics Limited
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jiangsu GDK Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Dirui Industrial Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alx Oncology Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cresco Labs Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Neumora Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking